ReviewActa parasitologica2026
Rhomboid Proteases in Plasmodium spp. : Biology, Functional Roles, and Therapeutic Potential.
Review in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMalaria continues to rank among the most significant and deadly infectious diseases, with over 282 million estimated cases and more than 610,000 deaths reported by the WHO in 2025. With the continuous rise of resistance to currently existing antimalarial drugs, there is a dire need to validate new drug targets. Evolutionarily conserved across eukaryotes, rhomboid proteases constitute a family of intramembrane serine proteases that play essential roles in parasite development, motility, and host cell invasion. This review summarizes the biology, structure, catalytic mechanism, and substrate specificity of Plasmodium rhomboid proteases, and critically evaluates their functional roles in parasite development, host-cell invasion, and potential as antimalarial drug targets.
methodsThe available literature on Plasmodium rhomboid protease biology, structural architecture, catalytic mechanism, substrate specificity, genetic essentiality, and emerging rhomboid-directed antimalarial therapeutic strategies was reviewed in a narrative format.
resultsAmong the eight Plasmodium rhomboid proteases, PfROM1 and PfROM4 are the best characterized, with PfROM4 serving as the main protease responsible for shedding key invasion-related adhesins (EBL, RBL, and MTRAP families) during erythrocyte invasion. Systematic knockout experiments demonstrated that PbROM4, PbROM6, and PbROM7 could not be deleted, establishing their essentiality in that species; however, recent inducible knockout studies have independently confirmed essentiality for PfROM4, PfROM6, and PfROM8 directly in P. falciparum. Parasite-selective inhibitors of PfROM4, including a peptide boronate and an α-ketoamide, have demonstrated the ability to block erythrocyte invasion and clear blood-stage parasitemia, providing the first proof of concept for rhomboid-targeted antimalarial therapy.
conclusionMost Plasmodium rhomboid proteases remain partially characterized or uncharacterized, and no experimental structure of a Plasmodium rhomboid has yet been solved. Recent development of parasite-selective inhibitors for PfROM4 offers an encouraging early proof of concept that this protease family can be pharmacologically targeted; however, this research was performed in vitro, and further investigation in animal models and against human rhomboids is required.
Indexed as
Identifiers
42747666What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.